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p62/Sqstm1 promotes malignancy of HCV-positive
hepatocellular carcinoma through Nrf2-dependent
metabolic reprogramming
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Yukio Tada10, Rika Obata11, Daisuke Yasuda11, Kyoko Takahashi11, Tsutomu Fujimura12, Jingbo Pi13,
Myung-Shik Lee14, Takashi Ueno12, Tomoyuki Ohe11, Tadahiko Mashino11, Toshifumi Wakai5, Hirotatsu Kojima10,
Takayoshi Okabe10, Tetsuo Nagano10, Hozumi Motohashi15, Satoshi Waguri7, Tomoyoshi Soga6,
Masayuki Yamamoto3, Keiji Tanaka2 & Masaaki Komatsu1
p62/Sqstm1 is a multifunctional protein involved in cell survival, growth and death, that is
degraded by autophagy. Ampliﬁcation of the p62/Sqstm1 gene, and aberrant accumulation
and phosphorylation of p62/Sqstm1, have been implicated in tumour development. Herein,
we reveal the molecular mechanism of p62/Sqstm1-dependent malignant progression, and
suggest that molecular targeting of p62/Sqstm1 represents a potential chemotherapeutic
approach against hepatocellular carcinoma (HCC). Phosphorylation of p62/Sqstm1 at Ser349
directs glucose to the glucuronate pathway, and glutamine towards glutathione synthesis
through activation of the transcription factor Nrf2. These changes provide HCC cells with
tolerance to anti-cancer drugs and proliferation potency. Phosphorylated p62/Sqstm1
accumulates in tumour regions positive for hepatitis C virus (HCV). An inhibitor of
phosphorylated p62-dependent Nrf2 activation suppresses the proliferation and anticancer
agent tolerance of HCC. Our data indicate that this Nrf2 inhibitor could be used to make
cancer cells less resistant to anticancer drugs, especially in HCV-positive HCC patients.
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p62/Sqstm1 (hereafter, p62) functions as a signalling hubthat determines whether cells survive, grow or die, by
activating the TRAF6 (TNF receptor-associated factor 6)-
NF-kB pathway, the mTORC1 (mammalian target of rapamycin
complex 1) pathway or caspase-8 and downstream effector
caspase pathways1,2. In addition, because p62 has the ability to
interact with both the autophagosome-localizing protein LC3 and
ubiquitin chains, it has been proposed to serve as an adaptor
between selective autophagy and ubiquitin signalling3. Indeed,
p62 localizes on autophagic cargos, including ubiquitin-positive
protein aggregates4, damaged mitochondria5 and invasive
bacterial cells6, and is ultimately degraded by autophagy7.
A growing body of evidence illustrates the interdependency
between the Keap1–Nrf2 pathway, one of the major cellular
defense mechanisms against oxidative and electrophilic stresses,
and p62-mediated selective autophagy8–13. When cytotoxic
ubiquitinated components such as damaged mitochondria and
invasive microbes appear, human p62 localizes to these structures
and is subsequently phosphorylated at Serine 349 (corresponding
to mouse Serine 351). Phosphorylated p62 binds with high
afﬁnity to Keap1 (Kelch-like ECH-associated protein 1), an
adaptor of the ubiquitin ligase complex for Nrf2 (nuclear factor
erythroid 2-related factor 2). This binding inhibits Keap1-driven
ubiquitination of Nrf2 and subsequently results in stabilization
of Nrf2, which then translocates into the nucleus to induce
the transcription of numerous cytoprotective genes encoding
antioxidant proteins, detoxifying enzymes and multidrug
transporters14,15. The ubiquitinated structures, along with
phosphorylated p62 and the Keap1 complex, are degraded by
autophagy, leading to elimination of cytotoxic components.
Dysregulation of the p62–Keap1–Nrf2 axis has been implicated
in tumour development. Spontaneous tumorigenesis is observed
in the livers of mice harbouring systemic mosaic deletion of Atg5
(Autophagy-related gene 5) or hepatocyte-speciﬁc disruption of
Atg7 (Autophagy-related gene 7)16,17. S351-phosphorylated p62
and Keap1 accumulate, and form aggregates, in tumours that are
defective for autophagy, resulting in persistent activation of Nrf2
(refs 9,16,17). Nrf2 activation by phosphorylated p62 contributes
to tumour growth, as demonstrated by the observation that
tumour size in liver-speciﬁc autophagy-deﬁcient mice is strikingly
reduced by simultaneous deletion of p62 or Nrf2 (refs17,18).
Similar to autophagy-deﬁcient tumours, p62 accumulation and
aggregate structures positive for phosphorylated p62 and Keap1
are frequently observed in human hepatocellular carcinoma
(HCC)9,19, and gene targeting of p62 in HCC cells suppresses
their growth in vitro and in vivo9. Recently, p62 was identiﬁed as
a pathogenic target of gains in 5q copy number in kidney cancer,
and elevated p62 is currently recognized as a causative factor in
renal cell carcinoma20. Furthermore, deletion of p62 is sufﬁcient
to suppress development of Ras-induced lung adenocarcinoma21;
conversely, elevation of the p62 level through constitutive
activation of K-Ras contributes to development of pancreatic
ductal adenocarcinoma (PDAC)22. However, the molecular
mechanism by which increased p62 stimulates tumour growth
remains largely unknown.
Here, we demonstrate that the S351-phosphorylated p62 causes
rearrangement of glucose and glutamine metabolism through
persistent activation of Nrf2, which provides HCC cells with both
tolerance to anti-cancer drugs and proliferation potency.
Furthermore, we identify a novel compound that inhibits Nrf2
activity by preventing the interaction between phosphorylated
p62 and Keap1, and may have potential as an anti-tumour drug.
Results
Metabolic proﬁling in HCC cells with phospho-mimetic p62.
Nrf2 positively regulates the expression of enzymes involved in
the pentose phosphate pathway (PPP), purine nucleotide
synthesis, glutathione synthesis and glutaminolysis (Fig. 1a). This
is especially true in tumour cells harbouring activated phospha-
tidylinositol 3-kinase-Akt, which promotes proliferation23. To
determine whether the p62–Keap1–Nrf2 pathway contributes to
metabolic reprogramming in tumour cells, we expressed FLAG-
tagged wild-type p62, phosphorylation-mimetic p62 (S351E) or
phosphorylation-defective p62 (S351A) in Huh7, a human HCC
cell line. Wild-type and mutant p62 proteins were expressed at
similar levels (Fig. 1b). As expected, expression of S351E, but not
the other alleles, was accompanied by nuclear accumulation of
Nrf2 (Fig. 1b). Ectopic expression of S351E induced expression of
typical Nrf2 target genes such as Nqo1 (NAD(P)H dehydrogenase
quinone 1), Mrps (multidrug resistance-associated proteins) and
Slc7a11/xCT, as well as genes encoding enzymes involved in the
PPP, glutathione synthesis and glutaminolysis (Fig. 2). In
addition, in S351E-expressing Huh7 cells, we observed marked
induction of Ugdh (UDP-glucose dehydrogenase) and Ugt1a1
(UDP-glucuronosyltransferase 1a1), both of which encode
enzymes related to the glucuronate pathway and thus
participate in the biosynthesis of glycosaminoglycans such as
hyaluronan, chondroitin sulfate and heparan sulfate, as well as
glucuronate conjugation of toxic drugs (Fig. 2). Unexpectedly, we
did not observe increased expression of genes encoding enzymes
involved in purine nucleotide synthesis in S351E-expressing
Huh7 cells (Fig. 2). In addition, we observed elevated levels of
proteins such as Pgd (phosphogluconate dehydrogenase), Gclc
(glutamate-cysteine ligase catalytic subunit) and Nqo1 in Huh7
cells expressing S351E (Fig. 1b). We veriﬁed the effect of S351E in
other cancer cell lines, including Hepa1, JHH1 and HepG2, in
which the endogenous levels of phosphorylated p62 were very low
(Figs 1b and 2). In contrast, no such effect was observed in Huh1
cells, which accumulate high levels of phosphorylated p62
probably due to the somatic mutation of Keap124 (Figs 1b and 2).
To elucidate the effect of p62 phosphorylation on cancer
metabolism, we performed metabolomic proﬁling in Huh7
cells after 48 h of overexpression of wild-type or mutant p62
(Supplementary Table 1). Huh7 cells expressing S351E contained
elevated levels of both UDP-glucose and UDP-glucuronate,
whereas cells expressing the wild-type protein or S351A mutant
did not (Fig. 3 and Supplementary Table 1). Meanwhile,
overexpression of S351E did not affect the amount of any PPP
metabolites (Fig. 3 and Supplementary Table 1). A tracer study
using [13C6] glucose revealed that metabolites of the PPP and
purine nucleotides, such as 13C5-Ru5P (ribulose-5-phosphate)
and 13C7-S7P (sedoheptulose-7-phosphate), were produced from
glucose, but their levels did not increase upon overexpression of
the S351E mutant (Fig. 4a and Supplementary Table 2). On the
other hand, although S351E overexpression decreased the amount
of 13C6-G6P (glucose-6-phosphate) and 13C6-G1P (glucose-1-
phosphate) as well as 13C6-UDP-glucose, it increased the
production of 13C6-UDP-glucuronate (Fig. 4a and Supplementary
Table 2). These metabolic changes were not observed in Huh7
cells expressing the S351A mutant (Fig. 4a and Supplementary
Table 2), suggesting that the increase of UDP-glucuronate
production is dependent on S351-phosphorylation of p62.
We also observed elevation of GSH (non-oxidized glutathione)
after 48 h of overexpression of the S351E, but not the other p62
alleles (Fig. 3 and Supplementary Table 1), suggesting that this
mutant facilitated GSH synthesis. In S351E-expressing Huh7,
the quantity of ophthalmate, an analogue of glutathione in which
the cysteine group is replaced by L-2-aminobutyrate25, was
signiﬁcantly higher than that in cells expressing wild-type or
S351A (Fig. 3 and Supplementary Table 1). We veriﬁed that GSH
production was elevated, by performing a tracer study with
[U-13C5] glutamine. Overexpression of S351E, but not S351A,
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affected glutathione synthesis: in particular, S351E decreased
amounts of 13C5-glutamate and increased amounts of
13C5-labelled GSH (Fig. 4b and Supplementary Table 3).
The carbons from glutamine were also distributed among
metabolites of the tricarboxylic acid cycle, including 13C5-2-OG
(2-oxoglutarate), 13C4-succinate and 13C4-malate, and amounts
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Figure 2 | Gene expression of Nrf2-targets in HCC cells harbouring phospho-mimetic p62. Quantiﬁcation of mRNA levels of Nrf2 target genes in the
indicated HCC cells expressing GFP, FLAG-p62 or its mutants. Values were normalized to the amount of mRNA in HCC cells expressing GFP. The
experiments were performed three times. Data are presented as means±s.e. *Po0.05, **Po0.01, ***Po0.001 as determined by the Welch t-test.
We used mouse p62 constructs in these experiments.
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Figure 1 | Activation of Nrf2 in HCC cells expressing phospho-mimetic p62. (a) Enzymes involved in glucose and glutamine metabolism regulated by
Nrf2. (b) Immunoblot analysis. FLAG-tagged p62 and its mutants were overproduced in the indicated HCC cells using an adenovirus vector. At 48 h after
infection, cytosolic and nuclear fractions were prepared and subjected to immunoblot analysis with the speciﬁed antibodies. Data were obtained from three
independent experiments.
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of the latter two metabolites decreased upon S351E
overexpression (Fig. 4b and Supplementary Table 3). Because
gene expression of Me1 (malic enzyme 1), which catalyses
oxidative decarboxylation of malate and production of NADPH,
was induced in Huh7 expressing S351E (Fig. 2), we predicted that
production of lactate would be elevated; however, we did not
detect 13C3-labelled lactate (Supplementary Table 3). These
results imply that Nrf2 activation by phosphorylated p62 causes
robust GSH production, resulting in decreased supply of
intermediates of the tricarboxylic acid from glutamine (not the
overall supply) in HCC cells.
Characterization of HCC cells with phospho-mimetic p62.
Production of GSH as well as UDP-glucuronate was elevated in
HCC cells expressing phospho-mimetic p62 (Fig. 3), and
expression of Mrps and Slc7a11/xCT was markedly induced in
these cells (Fig. 2), suggesting that these cells would be tolerant to
anti-cancer drugs. Indeed, ectopic expression of S351E, but not
wild-type or S351A, in Huh7 and Hepa1 signiﬁcantly alleviated
the growth-inhibitory effects of sorafenib, a small-molecule drug
used to treat kidney and liver cancers26, as well as those of
cisplatin, a drug used to treat many types of cancer27,28 (Fig. 5a).
Gene silencings of Mrps considerably reduced the effect of S351E
on anticancer agent resistance (Supplementary Fig. 1). No such
effect of S351E was observed in the case of Huh1, which
endogenously expresses high levels of phosphorylated p62
(Fig. 5a). Furthermore, Huh1 cells were less sensitive to anti-
cancer drugs than other HCC cells in which the endogenous
levels of phosphorylated p62 were low (Fig. 5a).
Next, we examined proliferation of HCC cells expressing
wild-type or mutant p62. Expression of wild-type and S351E
signiﬁcantly promoted proliferation in several HCC cell lines,
although not in Huh1; S351E-expressing cells grew more rapidly
than wild-type p62-expressing cells (Fig. 5b). In contrast, S351A
did not have any effect on proliferation (Fig. 5b). Moreover, we
veriﬁed the proliferation potency of S351E by measuring in vivo
tumorigenesis in a xenograft mouse model (Supplementary
Fig. 2). Because GSH contributes to cell proliferation as well as
redox balance and conjugation reactions29,30, we next sought to
determine whether the increase in cell number and tumour
volume upon overexpression of S351E was a result of elevated
GSH production. We cultured Huh-7 cells expressing green
ﬂuorescent protein (GFP) or S351E in the presence or absence of
buthionine sulfoximine (BSO), an inhibitor of g-glutamylcysteine
synthetase31, and veriﬁed that addition of BSO reduces GSH
concentrations (Fig. 5c), without affecting Nrf2 activation
(Fig. 5d). Importantly, BSO addition reduced the concentration
of GSH in S351E-expressing Huh7 cells back to control levels (the
level in GFP-expressing Huh7 cells in the absence of BSO,
Fig. 5c), and it also suppressed growth stimulation by S351E
(Fig. 5e). The treatment of Huh7 cells expressing GFP with BSO
decreased GSH level, but we did not recognize any statistically
signiﬁcant decrease of their growth compared with the Huh7 cells
without BSO treatment. Growth of Huh1 cells also tended to
decrease upon BSO treatment, although this effect was not
statistically signiﬁcant (Fig. 5e). These results suggest that
phosphorylation of p62 confers drug tolerance and proliferation
potency on HCC cells through a mechanism dependent on
increased GSH production.
Metabolic proﬁling in autophagy-deﬁcient mouse livers. To
examine the signiﬁcance of p62-mediated Nrf2 activation on
metabolic pathways in in vivo, we utilized mutant mice carrying a
hepatocyte-speciﬁc knockout of Atg7, an essential gene for
autophagy (Atg7f/f;Alb-Cre) and liver-speciﬁc Atg7- and Nrf2-
double-deﬁcient mice (Atg7f/f;Nrf2f/f;Alb-Cre)7,32. Loss of Atg7
caused not only inhibition of conversion of LC3-I to LC3-II, but
also accumulation of p62 as well as its S351-phosphorylated form,
implying defective autophagy7,9,33 (Fig. 6a). We observed
extensive co-localization of p62 and phosphorylated p62 in
aggregated structures of both Atg7f/f;Alb-Cre and Atg7f/f;Nrf2f/f;
Alb-Cre hepatocytes (Fig. 6b). Keap1 was also sequestered into
aggregate structures (Fig. 6b), suggesting that it is inactivated.
Indeed, the autophagy deﬁciency led to signiﬁcant accumulation
of nuclear Nrf2, which was lost by gene targeting of Nrf2 (Fig. 6a).
Microarray analysis showed the Nrf2-dependent expression of
numerous genes in autophagy-deﬁcient livers (Gene Expression
Omnibus (GEO) series accession number GSE65174). As
expected, multiple genes involved in the glucuronate pathway,
PPP, purine nucleotide synthesis and glutathione synthesis were
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induced in mutant livers (Fig. 6c). Such induction was cancelled
by additional loss of Nrf2 (Fig. 6c). We veriﬁed the Nrf2-
dependent increased protein levels such as Gclc and Ugdh in the
autophagy-deﬁcient liver (Fig. 6a).
Comprehensive metabolomic analyses showed elevated levels
of S7P, which is an intermediate of non-oxidative PPP, and
inosine monophosphate (IMP), ﬁrst product of purine nucleotide
synthesis, in autophagy-deﬁcient livers (Fig. 7 and Supplementary
Table 4). Although the quantity of glycogen in Atg7-deﬁcient
livers was less than that in control livers, some intermediates
of glucuronate pathway (that is, G1P, UDP-glucose and
glucuronate) in mutant livers were elevated (Fig. 7 and
Supplementary Table 4). Considering that NADPH level in
mutant livers was comparable to that in control livers (Fig. 7 and
Supplementary Table 4), these results imply that defective
autophagy drives the glucuronate pathway followed by
non-oxidative PPP and purine nucleotide synthesis. In addition,
non-oxidative PPP through glycolytic pathway may be also
accelerated in Atg7-deﬁcient livers because upstream glycolysis
intermediates but not downstream ones were elevated (Fig. 7 and
Supplementary Table 4). Further, we noticed marked elevation of
GSH in single Atg7-knockout livers (Fig. 7 and Supplementary
Table 4). Importantly, most metabolic changes recognized in the
autophagy-deﬁcient livers recovered to normal level by additional
loss of Nrf2 (Fig. 7 and Supplementary Table 5). The non-biased
enrichment analysis using Kyoto Encyclopedia of Genes
and Genomes (KEGG)34 on the basis of our microarray and
metabolomic analyses revealed signiﬁcant activations on several
metabolic pathways including ‘pentose and glucuronate
interconversions’ and ‘glutathione synthesis’ in autophagy-
deﬁcient livers (Supplementary Table 6). We veriﬁed that
liver-speciﬁc single Nrf2-32 or p62-knockout mice35 did not
exhibit any metabolic abnormality and that loss of p62 in
liver-speciﬁc Atg7-knockout background cancelled the metabolic
reprogramming as in the case of loss of Nrf2 (data not shown).
Taken together, we concluded that metabolic reprogramming
through the p62-mediated Nrf2 activation occurs in in vivo
mouse livers.
Speciﬁc accumulation of phospho-p62 in HCV-positive HCC.
To understand the role of the phosphorylated p62 in HCC
patients, we performed a series of experiments in a cohort of
patients with annotated clinicopathological data. To our surprise,
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immunoblot analysis of 17 HCC specimens revealed that both
p62 and its S349-phosphorylated form (corresponding to the
mouse S351-phosphorylated form) dramatically accumulated in
both tumour regions (4/4) and non-tumour regions (1/4) of
patients who were positive for anti-hepatitis C virus (HCV)
antibody (Fig. 8a). We also observed phosphorylated p62 in
non-tumour regions of one case each of alcoholic HCC (No. 16),
non-alcoholic HCC (No. 15) and combined hepatocellular and
cholangiocarcinoma (No. 14), although levels were much lower
than those in HCV-positive HCC (Fig. 8a). On the other hand,
phosphorylated p62 was barely detectable in tumour and
non-tumour regions of HCC patients positive for anti-hepatitis B
virus (HBV) antibody (Fig. 8a); the difference between HBV- and
HCV-positive patients was statistically signiﬁcant (Po0.001).
Keap1 levels were also elevated in HCV-positive HCC (Fig. 8a).
Immunohistochemical analysis with anti-p62 antibody revealed
abundant p62, as well as p62-positive aggregates, in all cases of
HCV-infected HCC (Fig. 8b). Likewise, aggregate structures
positive for S349-phosphorylated p62 and Keap1 were also pre-
sent in HCV-positive HCC (Fig. 8b), implying sequestration of
Keap1 into the p62-positive structures. In contrast, tissue adjacent
to HCC rarely contained S349-phosphorylated p62-positive
aggregates (Fig. 8b). As expected, double-immunoﬂuorescence
analysis with anti-p62 and anti-S349-phosphorylated p62 or anti-
p62 and anti-Keap1 antibodies revealed extensive co-localization
of S349-phosphorylated p62 and Keap1 in the p62-positive
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aggregate structures in HCV-positive HCC tumour cells (Fig. 8c).
We detected p62-positive aggregates in several cases of tumour
and non-tumour regions of other types of HCC, although they
were smaller and less numerous than those in HCV-positive HCC
(Fig. 8b and Supplementary Table 7). These aggregates contained
both S349-phosphorylated p62 and Keap1 (Supplementary
Table 7).
A speciﬁc inhibitor for Keap1 and phospho-p62 interaction.
The DLGex- and ETGE-binding motifs in the Neh2 domain of
Nrf2 bind individually to the same binding pocket at the bottom
surface of the DC (double glycine repeat and C-terminal region)
domain of Keap1 (refs 36,37; Fig. 9a), which forms a b-propeller
structure composed of six blades. One Nrf2 molecule binds to
each Keap1 homodimer; this interaction is crucial for rapid
ubiquitination of Nrf2. ETGE binds to Keap1 tightly, whereas the
Keap1–DLGex interaction is characterized as ‘fast-on and fast-
off’37. The binding of phosphorylated KIR (Keap1-interacting
region) of p62 is similar to that of ETGE, but the afﬁnity of the
former interaction is approximately ﬁvefold weaker9, implying
that phosphorylated p62 can eject only DLGex from Keap1
(Fig. 9a). On the basis of this evidence, we hypothesized that
speciﬁc inhibitor(s) of the interaction between S349-
phosphorylated p62 and Keap1 would recover the ability of
Keap1 to bind to Nrf2, and possibly function as an anti-tumour
drug for HCC (Fig. 9a).
To identify such compounds, we established a ﬂuorescence
polarization (FP)-based high-throughput screening (HTS)
method using recombinant Keap1-DC and the 6-FAM
(6-carboxyﬂuorescein)-labelled S349-phosphorylated peptide of
p62 using a previous report as a guide38. After screening 155,000
compounds, we identiﬁed one with the desired activity:
N-[2-acetonyl-4-(4-ethoxybenzenesulfonylamino)naphthalene-1-
yl]-4-ethoxybenzenesulfonamide, which we named K67 (Fig. 9b).
K67 is structurally analogous to Cpd16, a compound previously
identiﬁed by another group20 as an Nrf2 activator; speciﬁcally,
Cpd16 competes for interaction between Nrf2-ETGE and Keap1
(Fig. 9b). X-ray crystal structural analysis of the complex between
Keap1-DC and K67 revealed that like Cpd16, K67 binds to a
pocket surrounded by basic amino-acid residues at the bottom of
the b-propeller structure (Fig. 9c, Supplementary Figs 3, 4 and
Supplementary Table 8). The conformation of K67 reveals that
the naphthalene ring ﬁts into a pore formed by Gly364, Arg415,
Gly509 and Ala556 (Fig. 9c). The benzene ring of one
ethoxybenzene moiety interacts with Tyr525 (pi-stacking) and
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Arg483 (hydrophobic contact), and forms hydrogen bonding
with Ser508 (Fig. 9c). Although the benzene ring and ethoxy
group of the other ethoxybenzene moiety interact with Tyr334,
Tyr572 and Phe577, sulfonyl oxygen between naphthalene ring
and ethoxybenzene moiety interacts with Ser363, Ser602 and
Gly603 (Fig. 9c). In addition, water-mediated hydrogen bonds are
formed between K67 and the side chains of Ser555 and Arg415
(Fig. 9c and Supplementary Figs 5 and 6). The binding mode of
K67 to Keap1-DC was similar to that of Cpd16 (ref. 20;
Supplementary Figs 5 and 6); therefore, we speculated that K67
inhibits the interactions between Keap1 and both Nrf2-ETGE and
phosphorylated p62. However, an in vitro pull-down assay
revealed that neither K67 nor Cpd16 had any inhibitory effect
on the interaction of full-length Keap1 with Nrf2-ETGE
(indicated as Neh2[D17-51]) or full-length Nrf2 (Fig. 9d). By
contrast, the two compounds had comparable inhibitory effects
on the interaction between Keap1 and phosphorylated p62
(Fig. 9d).
Next, to investigate the interaction mode of DLGex and K67
or Cpd16 in the Keap1 pocket, we constructed a model of
the Keap1-DC–K67–DLGex complex by superposition of the
Keap1-DC from the Keap1-DC–K67 and Keap1-DC–DLGex
structures37. The complex model was generated by an energy-
minimizing calculation using the Crystallography and NMR
System software. The model illustrates the coexistence of DLGex
and K67 in the Keap1-DC (Nrf2-binding) pocket. A hydrogen
bond is formed between the carboxyl oxygen of DLGex peptide
Ser33 and the ethoxy oxygen from K67, and Gln26, Asp27,
Asp29, Leu30 and Val32 of DLGex and the ethoxy carbons of K67
engage in hydrophobic interactions (Fig. 9e). To compare the
binding mode between DLG and the inhibitory compounds
(K67 and Cpd16), we used Crystallography and NMR System to
construct a model of the Keap1-DC–Cpd16–DLGex complex
from the Keap1-DC–Cpd16 structure20. In this model, although
Cpd16 forms a hydrogen bond between the carboxyl oxygen of
DLGex peptide Ser33 and the methoxy oxygen of Cpd16, the
hydrophobic interactions differ from those between DLGex and
K67 (Fig. 9e); in particular, the effective hydrophobic interactions
between DLGex and Cpd16 are not present (Fig. 9e). Consistent
with this structural model, in vitro pull-down assays revealed that
Cpd16 but not K67 partially disturbed the interaction between
Nrf2-DLGex and full-length Keap1 (Fig. 9f). Further, we
conﬁrmed a tertiary complex comprised of K67, Keap1-DC and
Nrf2-DLGex by an in vitro pull-down assays with biotinylated
K67 (Fig. 9g). Unexpectedly, the amount of Nrf2-DLGex bound
to ‘Keap1-DC and biotinylated K67 complex’ was comparable to
that associated with ‘Keap1-DC and biotinylated Cpd16 complex’,
raising a possibility that biotinylation abolishes the advantage of
K67. Indeed, non-biotinylated Cpd16 had weaker effects than
non-biotinylated K67 on not only Nrf2-inhibition in Huh1 cells
but also proliferation of the cells (see Fig. 10 for details).
Therefore, we concluded that K67 is a speciﬁc inhibitor of the
interaction between phosphorylated p62 and Keap1.
K67 as a potential molecularly targeted drug for HCC. In
agreement with our in vitro results, treatment of Huh1 cells with
K67 dramatically inhibited the interaction between phosphory-
lated p62 and Keap1 (Fig. 10a). Concomitantly, it promoted the
interaction between Nrf2 and Keap1 because of the elevated level
of p62-free Keap1 (Fig. 10a). More importantly, ubiquitination of
Nrf2 was signiﬁcantly promoted by K67 treatment (Fig. 10b),
implying that Keap1, Nrf2 and K67 form a ternary complex in
cells, and that K67 restores the E3-ligase activity of Keap1. Cpd16
exerted a similar inhibitory effect on the interaction between
phosphorylated p62 and Keap1 (Fig. 10a), but did not promote
ubiquitination of Nrf2 (Fig. 10b). On the basis of these results,
we hypothesized that K67 inhibits Nrf2 by facilitating Nrf2
degradation. Indeed, the amount of Nrf2 in both nuclear and
cytosolic fractions of Huh1 cells markedly decreased after
treatment with K67 (Fig. 10c, left panel), a trend that continued
during long-term K67 treatment (Fig. 10c). In contrast to the
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reduction in Nrf2, Keap1 accumulated in a time-dependent
manner (Fig. 10c). Similar effects were also observed in the case
of Cpd16, although quite less efﬁciency (Fig. 10c). In addition,
we conﬁrmed that K67 suppressed the expression of Nrf2 target
genes (Fig. 10d). The non-biased enrichment analysis based on
microarray analysis revealed that K67 has speciﬁc inhibitory
effect on induction of Nrf2-targets including genes encoding
enzymes related to ‘pentose and glucuronate interconversions’
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and ‘glutathione synthesis’ (Supplementary Table 9 and GEO
series accession number GSE68679). Remarkably, proliferations
of Huh1 cells and of Huh7 cells expressing phospho-mimetic p62
was dramatically suppressed by K67 treatment (Fig. 10e and
Supplementary Fig. 7). Cpd16 also exerted the growth inhibitory
effect, although less efﬁcacy (Fig. 10e). As shown in Fig. 3a,
Huh1 cells were less sensitive than other HCC cells to treatment
with either sorafenib or cisplatin, but pre-treatment with K67
signiﬁcantly increased their sensitivity to both drugs (Fig. 10f),
and tumour cell death was markedly induced by treatment
with sorafenib in combination with K67 (Fig. 10f). Similar
effect of K67 was observed in the case of Huh7 expressing
phospho-mimetic p62 (Supplementary Fig. 7), but not parental
Huh7 cells (Fig. 10e,f).
Discussion
In this study, we discovered a novel form of metabolic
reprogramming mediated by the p62–Keap1–Nrf2 axis, which
makes an important contribution to tumour growth and drug
resistance of HCC. Further, we identiﬁed an inhibitor of Nrf2
activation and proved that it reduces proliferation potency and
anticancer agent tolerance of HCC cells (Fig. 10g).
HCV infection is the leading cause of chronic liver diseases,
causing the progression of liver disease from chronic hepatitis to
cirrhosis, with the complications of liver failure and HCC. How is
the p62–Keap1–Nrf2 pathway activated in HCC cells? Aggregate
structures positive for phosphorylated p62 and Keap1 were
present in tumour regions in HCV-positive HCC patients,
implying robust activation of Nrf2 (Fig. 8). Infection by both
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Figure 10 | Inhibitory effects of K67 on tumour growth and tolerance to anti-cancer agents. (a) Immunoprecipitation assays. Huh1 cells expressing
FLAG-Keap1 were cultured in the presence or absence of indicated compound (50mM) for 12 h. The immunoprecipitant with anti-FLAG antibody was
subjected to immunoblot analysis. Experiments were performed three times. (b) Ubiquitination of Nrf2. Huh7 cells expressing S351E were cultured in the
presence or absence of indicated compound (50mM). After 4 h of treatment, the cells were treated with or without lactacystin (10mM) for 8 h. The
immunoprecipitant with anti-Nrf2 antibody was subjected to immunoblot analysis. Experiments were performed three times. (c) Immunoblot analysis.
Huh1 cells were cultured in the presence of 50mM K67 or Cpd16 for the indicated times. Cytosolic and nuclear fractions were prepared and subjected to
immunoblot analysis. Experiments were performed three times. (d) Quantiﬁcation of mRNA levels of Nrf2 target genes in Huh1 cells treated with 50mM
K67 for the indicated times. Values were normalized to the amount of mRNA in non-treated Huh1 cells. Experiments were performed three times. Data
represent means±s.e. *Po0.05, **Po0.01, ***Po0.001 as determined by the Welch t-test. (e) Effect of K67 on cell proliferation. Huh1 and Huh7 cells
were pre-cultured in the presence of DMSO, K67 or Cpd16. Proliferation was measured starting at 72 h after pre-culture (n¼4). Initial cell numbers were
normalized to 1. Experiments were performed three times. Data represent means±s.e. *Po0.05, **Po0.01, ***Po0.001 as determined by the Welch
t-test. (f) Effect of K67 on resistance to anti-cancer drugs. Huh1 and Huh7 cells were pre-cultured in the presence of DMSO or K67 for 96 h. Thereafter, the
cells were treated with sorafenib, cisplatin or either drug in combination with K67 for 48 h, and survival ratio was determined (n¼4). Experiments were
performed three times. Data represent means±s.e. *Po0.05, **Po0.01, ***Po0.001 as determined by the Welch t-test. (g) Schematic diagram of cancer
malignancy mediated by the p62–Keap1–Nrf2 axis.
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HCV and HBV induces autophagosome formation, but only
the former suppresses fusion between autophagosomes and
the lysosome in order to promote viral replication on or around
autophagosomes39,40. In addition, p62 is a stress-inducible
protein whose expression is regulated by Nrf2 (ref. 10), and
p62 overproduction is sufﬁcient for phosphorylation of p62 to
inactivate Keap1 (ref. 9), resulting in a positive-feedback loop that
accelerates Nrf2 activation. Thus, chronic inﬂammation in
patients persistently infected with HCV, together with impaired
maturation of autophagosomes in HCV-infected HCC, would
result in the phosphorylation of S349 of p62 followed by Nrf2
activation. Somatic mutations of either Nrf2 or Keap1 are
frequently detected in cancers, including HCC; thus, both genes
are recognized as cancer drivers41–43. Such mutations result in
alteration or impairment of the interaction between Keap1 and
Nrf2, followed by persistent activation of Nrf2, which makes
tumour cells resistant to oxidative damage and anticancer
agents41. Nrf2 is also activated in certain types of cancer even
in the absence of these somatic mutations. For instance, in type 2
papillary renal cell carcinomas that carry mutations in fumarate
hydratase, Keap1 is succinated, leading to hyperactivation of Nrf2
(refs 44,45). Because p62 is an Nrf2 target gene10, p62 protein
should accumulate and be phosphorylated in tumour cells
harbouring mutations of either Nrf2 or Keap1, as well as in the
renal cell carcinomas with succinated Keap1. As a result, p62
would inactivate normal Keap1 protein synthesized from the
Keap1-allele without the mutation, leading to a vicious circle of
Nrf2 activation in the tumour cells. Accordingly, it is plausible
that the p62-mediated Nrf2 activation occurs in various types of
tumour cells in addition to HCV-positive HCC (Fig. 10g).
How does the p62–Keap1–Nrf2 axis promote tumour
malignancy? Consistent with a previous study23, we observed a
marked induction of genes encoding enzymes involved in PPP,
glutathione synthesis and glutaminolysis in the HCC cells
expressing phospho-mimetic p62 (Figs 1 and 2). However, our
metabolomic analyses revealed that p62-mediated Nrf2 activation
in HCC cells facilitates the glucuronate pathway and glutathione
synthesis but not the PPP, purine nucleotide synthesis or
glutaminolysis (Figs 3 and 4). These lines of evidence suggest
that Nrf2 affects various metabolic pathways in tumour cells, but
the inﬂuenced pathway(s) differs among types of tumour cells
and/or the genetic background. In addition to elevated synthesis
of UDP-glucuronate and glutathione, expression of Mrps and
Slc7a11/xCT, which mediate glutathione export and homeostasis,
was markedly induced in the HCC cells (Figs 1 and 2). Therefore,
in HCC cells with S349-phosphorylated p62, anticancer agents
could be easily conjugated with GSH and glucuronic acid and
subsequently exported through Mrps to the extracellular space,
leading to tolerance against anti-cancer drugs. In addition to its
involvement in redox balance and conjugation reactions, GSH
promotes cell proliferation29,30. Indeed, treatment of the HCC
cells with a pharmacological inhibitor of glutathione synthesis
was sufﬁcient to suppress their growth (Fig. 5). Therefore, we
propose that metabolic reprogramming through the p62–Keap1–
Nrf2 pathway stimulates growth of HCC cells and increases their
tolerance to anti-cancer drugs (Fig. 10g). F6P (Fructose-6-
phosphate) in Huh7 cells expressing S351E tended to decrease,
whereas the UDP-GlcNAc (UDP-N-acetylglucosamine) increased
(Supplementary Table 1), raising a possibility that the
hexosamine pathway is also enhanced by the p62–Keap1–Nrf2
axis and involved in tumour development.
There were apparent differences of metabolic reprograming
between ‘Huh7 cells expressing phospho-mimetic p62’ and
‘Atg7-deﬁcient mouse livers’, both of which showed the
p62-mediated Nrf2 activation. Although the PPP in the
Atg7-deﬁcient mouse livers was likely to be accelerated (Fig. 7),
that in HCC cells harbouring S351E p62 was not (Figs 3 and 4).
In contrast with higher glucuronate level in mutant livers than
control (Fig. 7), we did not detect such increase in the HCC.
Further, increases of G1P and of upstream intermediates of the
glycolytic pathway were recognized only in mutant livers (Fig. 7).
One possible explanation is that loss of Atg7 is accompanied
by impairment of autophagy, which affects metabolic
pathways including b-oxidation46 and gluconeogenesis47
directly (not only through the Nrf2-activation). Inconsistencies
in their metabolisms might arise from results of the inﬂuence of
defective autophagy for glucose and lipid metabolism.
In a chemical screen, we identiﬁed K67, a small compound that
inhibits the interaction between phosphorylated p62-peptide
and Keap1. Our modelling studies indicate that K67 binds to a
pocket within Keap1 that is involved in the interactions
with Nrf2-ETGE, Nrf2-DLGex and phosphorylated p62 (Fig. 9).
The unique feature of K67, distinct from those of other
Keap1-interacting compounds such as Cpd16, is that it can
inhibit the interaction between phosphorylated p62 and Keap1
without exerting any effect on the interaction between Nrf2 and
Keap1. Speciﬁcally, K67 removed phosphorylated p62 from
Keap1 and restored the E3-ligase adaptor activity of Keap1 in
HCC cells, resulting in ubiquitination and degradation of Nrf2.
Our results clearly showed that treatment of HCC cells with K67
suppressed proliferation and reduced tolerance to anticancer
agents (Fig. 10). K67 inhibits Nrf2 by targeting Keap1. Therefore,
K67 might serve as a drug against cancer cells that are resistant to
anti-cancer agents in a manner that depends upon p62 (Fig. 10g).
Note that, due to its lower solubility, we need to develop
the derivatives with higher solubility, in considering the
pharmacological effect for human therapy.
Cancer cells are addicted to autophagy because this protein
degradation system plays important roles in both quality control
of organelles, such as mitochondria and peroxisomes, and the
supply of amino acids and fatty acids to support survival
and proliferation under metabolic stress conditions48. In fact,
K-Ras-driven tumorigenesis in a mouse model for non-small-cell
lung cancer is suppressed by loss of autophagy49,50. Based on
such evidence, clinical trials are underway in which various
cancers are being treated with a combination of existing
anticancer drugs and autophagy inhibitors such as chloroquine
and hydroxychloroquine51,52. However, in a genetically
engineered mouse model of PDAC, the role of autophagy in
tumour development is intrinsically linked to p53 status53. Mice
with pancreas-speciﬁc activated oncogenic K-Ras develop PDAC,
which is prevented by loss of autophagy53. Surprisingly, however,
in mice harbouring oncogenic K-Ras but lacking Trp53 (usually
identiﬁed as PDAC genetic background), loss of autophagy
no longer blocks tumour progression, but instead accelerates
tumour onset53. One possible explanation is that loss of Trp53
enhances glucose uptake and enrichment of anabolic pathways,
which can fuel tumour growth54. Concomitantly, because p62
should accumulate in autophagy-deﬁcient tumours or in tumours
of patients who receive chloroquine or hydroxychloroquine, it is
plausible that Nrf2 is robustly activated in tumour cells and
directs their metabolism into anabolic pathways advantageous to
their growth. Indeed, our comprehensive metabolomic and gene
expression analyses of the livers of hepatocyte-speciﬁc Atg7-,
p62-, Nrf2-, Atg7 p62- and Atg7 Nrf2-deﬁcient mice conﬁrmed
metabolic reprogramming mediated by the p62–Keap1–Nrf2 axis
in autophagy-deﬁcient livers (Figs 6 and 7); such reprogramming
contributes to tumour development in autophagy-deﬁcient mouse
livers17,18. Therefore, rather than suppressing tumours by
inhibiting autophagy, the synergistic facilitation of anabolic
pathways due to loss of p53 together with activation of Nrf2
may promote tumour progression and abolish the requirement
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for autophagy. Therefore, in clinical trials of anticancer
treatments based on inhibition of autophagy, it is essential to
consider the gene variation related to cancer metabolism, for
example, Trp53 status as well as Nrf2 signalling.
Methods
Cell culture. Media and reagents for cell culture were purchased from Life
Technologies. HCC cell lines were purchased from the Health Science Research
Resources Bank. All cells were conﬁrmed negative for mycoplasma contamination
before use. Some stocks of JHH-1 have been shown to be misidentiﬁed by
International Cell Line Authentication Committee, but authentic stocks
(JCRB1062) are known to exist. We obtained the original stock (JCRB1062) from
JCRB cell bank and the cell line has been authenticated in JCRB by short-tandem
repeat-PCR and isozyme analysis. Mouse p62 and mutant adenoviruses were
prepared using the Adenovirus Expression Vector Kit (TAKARA BIO). To express
exogenous p62 and the mutant p62 proteins in HCC cell lines, HCC cell lines were
plated onto six-well dishes for cell biological analyses or onto 15-cm dishes for
metabolome analyses. At 24 h after plating, the medium was replaced with fresh
medium containing adenovirus at a multiplicity of infection of 50. For the glucose
tracer study, cells were washed with PBS 48 h after infection and incubated in
glucose-free medium supplemented with 10mM [U-13C6] glucose (Cambridge
Isotope Laboratories) for 1 h. For the glutamine tracer study, cells were
washed with PBS 48 h after infection and incubated in glutamine-free medium
supplemented with 4mM [U-13C5] glutamine (Cambridge Isotope Laboratories).
Cell viability in proliferation and cytotoxicity assays was measured using the Cell
Counting Kit-8 (Dojindo). For knockdown of Mrps, Huh7 cells were transfected
with 25 nM SMARTpool short interfering RNAs targeting Mrp1 (M-007308-01),
Mrp2 (M-004225-01) and Mrp5 (M-007314-02) using Dharmafect 1 (Thermo
Scientiﬁc). Tumour formation in nude mice by subcutaneous injection was
performed as described elsewhere55. For tumorigenicity assays, ten mice were used
per cell line. Tumour growth was monitored by measuring tumour volume 35 days
after the injection.
Mice. Atg7f/f and Atg7f/f;Alb-Cre mice with C57BL/6 genetic background7 were
used in this study. p62f/f and Nrf2f/f mice were bred with Atg7f/f;Alb-Cre mice to
generate Atg7f/f;p62f/f;Alb-Cre and Atg7f/f;Nrf2f/f;Alb-Cre mice, respectively. p62
and Nrf2-conditional knockout mice with C57BL/6 genetic background were
previously described32,35. Mice were housed in speciﬁc pathogen-free facilities, and
the Ethics Review Committee for Animal Experimentation of Niigata University of
the Tokyo Metropolitan Institute of Medical Science and of Tohoku University
approved the experimental protocol.
Immunoblot analysis. Livers were homogenized in 0.25M sucrose, 10mM
2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid (HEPES; pH 7.4) and
1mM dithiothreitol. Nuclear fractions from livers were prepared using the NE-PER
Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientiﬁc). Samples
were separated using a NuPAGE system (Life Technologies) on 4–12% Bis-Tris gels
in MOPS-SDS buffer, and then transferred to a polyvinylidene diﬂuoride
membrane. Antibodies against Atg7 (013-22831, Wako Pure Chemical Industries,
Ltd.; the dilution ratio is 1:1,000), Pgd (ab96225, Abcam; the dilution ratio is
1:500), Gclc (ab41463, Abcam; the dilution ratio is 1:500), p62 (GP62-C, Progen
Biotechnik GmbH; the dilution ratio is 1:1,000), Nqo1 (ab34173, Abcam; the
dilution ratio is 1:1,000), Nrf2 (H-300, Santa Cruz Biotechnology; the dilution ratio
is 1:200), LC3B (#2775, Cell Signaling Technology; the dilution ratio is 1:500),
Ugdh (ab155005, Abcam; the dilution ratio is 1:500), Keap1 (10503-2-AP,
Proteintech Group; the dilution ratio is 1:500), Slc7a11/xCT (ab175186, Abcam; the
dilution ratio is 1:500), ubiquitin (D058-3, Medical & Biological Laboratories;
the dilution ratio is 1:500), actin (MAB1501R, Merck Millipore Headquarters; the
dilution ratio is 1:1,000) and Lamin B (M-20, Santa Cruz Biotechnology;
the dilution ratio is 1:200) were purchased from the indicated suppliers.
Anti-phosphorylated p62 polyclonal antibody (the dilution ratio is 1:500) was
raised in rabbits using the peptide CysþKEVDP(pS)TGELQSL as an antigen9.
Blots were then incubated with horseradish peroxidase-conjugated secondary
antibody (Goat Anti-Mouse IgG (Hþ L), 115-035-166, Jackson ImmunoResearch;
Goat Anti-Rabbit IgG (Hþ L) 111-035-144; Goat Anti-Guinea Pig IgG(Hþ L)
106-035-003; Donkey Anti-Goat IgG (Hþ L) 705-035-003; the dilution ratio is
1:10,000) and visualized by chemiluminescence. Images have been cropped for
presentation. Full size images are presented in Supplementary Figs 8–11.
Quantitative real-time PCR. Using the Transcriptor First-Strand cDNA Synthesis
Kit (Roche Applied Science), cDNA was synthesized from 1 mg of total RNA.
Quantitative PCR was performed using LightCycler 480 Probes Master (Roche
Applied Science) on a LightCycler 480 (Roche Applied Science). Signals from
human samples were normalized against GAPDH (glyceraldehyde-3-phosphate
dehydrogenase).
The sequences of the primers used in analysis of human cell lines and of mouse
livers were shown in Supplementary Table 10.
Metabolome analysis. Liver tissues were snap-frozen in liquid nitrogen.
Frozen liver tissue (B60mg) were immediately plunged into 500 ml of methanol
containing 20 mM each of three internal standards (methionine sulfone (Wako),
D-camphor-10-sulfonic acid (Wako) and 2-(n-morpholino)ethanesulfonic acid
(Dojindo)) and Zirconia Beads, and homogenized at 1,500 r.p.m. for 5min at 4 C
using Shake Master NEO (Biomedical Science) to inactivate enzymes. Next, 200 ml
of Milli-Q water and 500 ml of chloroform were added, and the solution was
centrifuged at 4,600g for 15min at 4 C. The upper aqueous layer (300 ml) was
centrifugally (at 9,100g for 5 h at 4 C) ﬁltered through a Millipore 5-kDa cutoff
ﬁlter to remove proteins. The ﬁltrate was lyophilized and dissolved in 50 ml of
Milli-Q water containing 200 mM each of 3-aminopyrrolidine (Sigma-Aldrich) and
trimesate (Wako) before capillary electrophoresis (CE)-time-of-ﬂight mass spec-
trometry (TOFMS) analysis. In the case of metabolomic analysis with cells, cells
(1 106) were washed twice with 10ml of 5% mannitol, and then 1ml of methanol
containing 25 mM of each three internal standards was added to cells. Thereafter,
the cells were soaked for 10min to obtain sample solution. Next, 200ml of Milli-Q
water and 400 ml of chloroform were added to the sample (400 ml), and the solution
was centrifuged at 10,000g for 3min at 4 C. The upper aqueous layer (400 ml) was
centrifugally (at 9,100g for 3 h at 4 C) ﬁltered through a Millipore 5-kDa cutoff
ﬁlter to remove proteins. The ﬁltrate was lyophilized and dissolved in 25 ml of
Milli-Q water containing 200 mM each of 3-aminopyrrolidine (Sigma-Aldrich) and
trimesate (Wako) before CE-TOFMS analysis.
CE-TOFMS was carried out using an Agilent CE Capillary Electrophoresis
System equipped with a G3250AA LC/MSD TOF mass spectrometer, 1100 isocratic
HPLC pump, G1603A CE-MS adapter kit and G1607A CE-ESI-MS sprayer kit
(Agilent Technologies). For anionic metabolite proﬁling, the original Agilent
stainless steel ESI needle was replaced with an Agilent G7100-60041 platinum
needle56. The system was controlled using the Agilent G2201AA ChemStation
software version B.03.01 for CE (Agilent Technologies). Cationic metabolites were
analysed using a fused-silica capillary (50 mm i.d. 100 cm total length), with 1M
formic acid as the electrolyte57,58. The sample was injected at a pressure of 50mbar
for 3 s (B3 nl). The applied voltage was set at 30 kV. Electrospray ionization–mass
spectrometry (ESI-MS) was conducted in positive-ion mode, and the capillary
voltage was set at 4 kV. Methanol/water (50% v/v) containing 0.1 mM hexakis
(2,2-diﬂuorothoxy)phosphazene was delivered as the sheath liquid at 10 ml min 1.
ESI-TOFMS was performed in positive-ion mode, and the capillary voltage was set
at 4 kV. The ﬂow rate of heated dry nitrogen gas (heater temperature, 300 C) was
maintained at 10 psig. At TOFMS, the fragmentor, skimmer and Oct RFV voltages
were set at 75, 50 and 125V, respectively. Automatic recalibration of each acquired
spectrum was performed using reference masses of reference standards
([13C isotopic ion of protonated methanol dimer (2MeOHþH)]þ , m/z 66.0632)
and ([Hexakis (2,2- diﬂuorothoxy)phosphazene þH]þ , m/z 622.0290). Exact
mass data were acquired at a rate of 1.5 spectra per s over an m/z range of
50–1,000. Other conditions were as described for the cation analysis. Anionic
metabolites were analysed using a cationic polymer-coated COSMO(þ ) capillary
(50 mm i.d. 110 cm; Nacalai Tesque) with 50mM ammonium acetate (pH 8.5)
as the electrolyte59. The sample was injected at a pressure of 50mbar for 30 s
(B30 nl). The applied voltage was set at  30 kV. ESI-MS was conducted in
negative-ion mode, and the capillary voltage was set at 3.5 kV. Other conditions
were as described for the anion analysis56. Raw data obtained by CE-TOFMS were
processed using the MasterHands software60. Signal peaks corresponding to
isotopomers, adduct ions and other product ions of known metabolites were
excluded. All signal peaks potentially corresponding to authentic compounds were
extracted, and their migration time (MT) values were normalized using those of the
internal standards. Thereafter, the alignment of peaks was performed according to
the m/z and normalized MT values. Finally, peak areas were normalized against
those of the internal standards, MetSul for cations and CSA for anions. The
resulting relative-area values were further normalized by sample amount.
Annotation tables were produced from CE-ESI–TOFMS measurement of standard
compounds and aligned with the data sets according to similar m/z values and
normalized MT values. We identiﬁed metabolites by comparing their m/z values
(mass accuracy of 20 p.p.m.) and MTs (time accuracy of 0.2min) with metabolite
standards. For quantiﬁcation, to correct for the loss of analyte during sample
preparation, we used internal standardization technique and then quantiﬁcation
was performed by comparing their peaks against a calibration curves generated
using 513 metabolite standards. The annotation table was added as a
Supplementary Data 1.
Histological examination. Human and mouse livers were ﬁxed by immersion in
10% neutral buffer formalin with PhosSTOP (Roche Applied Science) and 4%
paraformaldehyde/4% sucrose in 0.1M phosphate buffer, pH 7.4. After rinsing,
samples were embedded in parafﬁn for staining with the indicated antibodies.
Human tissue samples. Specimens of HCC patients during surgical operations
were prepared for immunoblot and histological analyses. This part of the study
protocol was approved by the Institutional Review Board of Niigata University
Graduate School of Medicine and Dental Science (approved No. 643), and
informed consent was obtained from all patients involved in the current study.
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Immunoﬂuorescence and immunohistochemical analyses. Sections were
incubated for 2–3 days at 4 C with the following primary antibodies: guinea-pig
polyclonal antibody against p62 (Progen), rabbit polyclonal antibody against
phosphorylated p62 and rabbit polyclonal antibody against Keap1 (Proteintech
Group). Double-immunoﬂuorescence staining for p62 and phosphorylated p62 or
p62 and Keap1 was performed using Dylight549-conjugated goat anti-guinea pig
IgG (Jackson ImmunoResearch Laboratories) and Alexa Fluor-488-conjugated
donkey anti-rabbit IgG (Invitrogen) as secondary antibodies. Immunoﬂuorescence
images were obtained with a laser scanning confocal microscope (FV1000,
Olympus) equipped with a  40 objective lens (UPlanSApo, oil, numerical
aperture 1.3, Olympus). After image acquisition, contrast and brightness were
adjusted using Photoshop CS4 (Adobe Systems). Immunohistochemistry was also
performed using the same primary antibodies as for immunoﬂuorescence. After
incubation with primary antibodies, sections were incubated with biotinylated
secondary antibodies for 30min, followed by exposure to streptavidin-peroxidase
complex for 10min. Diaminobenzidine was used as the chromogen, and the
sections were counterstained with haematoxylin. Normal mouse immunoglobulin
was substituted for the primary antibodies as the negative control. Immuno-
reactivity of p62, phosphorylated p62 and Keap1 was evaluated by comparison with
negative controls. The expression of each antibody was deﬁned as the presence of
cytoplasmic and/or nuclear immunoreactivity; the expression was judged positive
when either single cell or cell clusters showed immunoreactivity for each antibody,
and negative when no immunoreactivity for each antibody was observed
throughout the examined areas.
Chemical compound screening. FAM-labelled phospho-p62 peptide
(FAM-VDP(pS)TGELQ-NH2) was purchased from Toray Research Center (Tokyo,
Japan). GST-His-Keap1-DC (amino acids 321–609) was expressed in Escherichia
coli and puriﬁed by chromatography on glutathione–Sepharose 4B resin
(Amersham Biosciences). HTS by FP assay was performed in 384-well non-binding
black plates (784900 Greiner Bio-One, Greiner Bio-One GmbH). Five microlitres
of 20 nM peptide solution and 5 ml of 500 nM protein solution diluted with FP
assay buffer (10mM HEPES, pH 7.4, 0.5mM EDTA, 150mM NaCl, 0.005%
Tween-20) were dispensed to each well where 100 nl of 1mM compound solution
(dimethylsulphoxide (DMSO)) was transferred in advance by an Echo 550 liquid
handler (Labcyte). Subsequently, the plates were incubated for 30min at room
temperature. The FP signal was measured at 520 nm with excitation at 485 nm by a
PHERAStar plate reader (BMG Labtech)38. Chemical library containing about
155,000 compounds (Drug Discovery Initiative, University of Tokyo) was subjected
to this HTS.
Compound (K67) characterization data. 1H NMR (500 MHz, DMSO-d6):
d 10.10 (brs, 1H), 9.72 (brs, 1H), 7.92 (d, J¼ 8.6Hz, 1H), 7.58 (dd, J¼ 6.8, 2.0Hz,
2H), 7.50 (d, J ¼ 8.6Hz, 1H), 7.34 (dd, J¼ 6.8, 2.0Hz, 2H), 7.28 (dd, J¼ 8.6,
7.1Hz, 1H), 7.15 (dd, J¼ 8.6, 7.1Hz, 1H), 7.05 (s, 1H), 6.95 (dd, J¼ 6.8, 2.0Hz,
2H), 6.92 (dd, J¼ 6.8, 2.0Hz, 2H), 4.01–4.07 (m, 4H), 3.77 (brs, 2H), 2.01 (s, 3H),
1.28–1.33 (m, 6H); 13C NMR (150MHz, DMSO-d6): d 204.8, 161.7, 132.7, 132.0,
131.8, 128.9, 128.8, 128.7, 125.7, 125.3, 124.0, 122.9, 114.6, 114.5, 63.6, 46.2, 29.6,
14.3; HRMS (m/z): [M–H]– calculated for C29H29N2O7S2, 581.1416; found,
581.1391.
1H NMR spectra (500MHz) were measured on a Varian 500 FT-NMR (Varian
Medical Systems) with tetramethylsilane as an internal standard (d¼ 0.00).
13C NMR spectra (150MHz) were measured on a JEOL JNM-ECP600 FT-NMR
(JEOL) and the chemical shifts were referenced relative to the signal of DMSO-d6
(d¼ 39.5). Mass spectra were recorded on a JEOL JMS-T100LP AccuTOF LC-plus
4G mass spectrometer (ESI-MS).
Crystallization and data collection. Keap1-DC with an N-terminal 6His tag
was puriﬁed and concentrated to 12mgml-1 by ultraﬁltration in a buffer containing
1mM TCEP (tris(2-carboxyethyl)phosphine) and 20mM Tris-HCl (pH 7.5).
A 1.0-ml aliquot of a mixture containing a 1:1.2 molar ratio of Keap1-DC to K67
was mixed with 1.0 ml of crystallization solution and equilibrated by sitting drop
vapour diffusion against 100ml of reservoir solution. Crystals were obtained in a
drop containing 100mM sodium-HEPES (pH 7.5), 2.0M ammonium formate
and 3% (w/v) 1,6-hexanediol at 4 C. The crystals were harvested directly and
ﬂash-cooled in liquid nitrogen. X-ray diffraction data sets were collected at 100 K
on BL44XU at SPring-8 (Harima; X-ray wavelength, 0.9 Å). Data processing and
reduction were conducted using HKL-2000 (ref. 61).
Structure determination and reﬁnement. The structure of the complex of
Keap1-DC and K67 was solved by molecular replacement using the program
MOLREP62 with the free-form Keap1-DC structure as a search model (Protein
Data Bank accession number 3WDZ). Multiple rounds of manual ﬁtting and
reﬁnement were carried out using the programs Coot63 and REFMAC5 (ref. 64).
In the resultant Fo–Fc omit map, the electron-density map clearly showed the
presence of K67. Potential ambiguities of K67 model in the electron density map,
such as acetyl (CH3CO-) moieties were determined using hydrogen atom contacts
in the choice of orientation. The ﬁnal Keap1-DC model shows amino acids
325–609. Data reduction and reﬁnement statistics are summarized in
Supplementary Table 8. Potential hydrogen bonds and van der Waals contacts were
analysed using the program LIGPLOT65. Molecular graphics were prepared using
PyMOL.
Pull-down assay. Puriﬁed Keap1 (1 mM) was pre-treated with or without the
indicated compounds in pull-down assay buffer (20mM Tris-HCl (pH 7.5),
150mM NaCl, 0.5% NP-40, 0.5mM TCEP), and then 6His-GST-Neh2(1-56)
(1 mM) or 6His-GST-Neh2(D17-51) (1 mM) was added to the mixture. The
pull-down complexes were collected with Ni-NTA magnetic beads and washed
with pull-down assay buffer containing 20mM imidazole. The pulled-down
protein complexes were eluted with 300mM imidazole and analysed by
SDS–PAGE, followed by staining with Oriole ﬂuorescent gel stain (Bio-Rad). The
band intensity of Keap1 was quantitated on a ChemiDoc XRSþ System (Bio-Rad).
OSF-S349-phosphorylated p62- or OSF-Nrf2-bound Strep-Tactin Sepharose was
incubated with Keap1 (0.06 mM) in pull-down assay buffer with or without the
indicated compounds. The pulled-down protein complexes were washed with
pull-down assay buffer, and the resultant samples were subjected to western
blotting with anti-FLAG and anti-Keap1 antibodies. Band intensity of the Keap1
was determined using the NIH image software. Biotinylated compound that carries
a biotin on one of the ethoxy group of K67 or Cpd16 through a linker was
synthesized as follows: the precursor that has a propargyloxy group in place
of the ethoxy group of K67 or Cpd16 prepared, and then conjugated with
Azide-PEG3-biotin (Sigma-Aldrich) by Huisgen azide-alkyne 1,3-dipolar
cycloaddition reaction. Biotinylated K67 (400 mM) or Cpd16 (400 mM) was
conjugated to Streptavidin Mag Sepharose (GE Healthcare UK Ltd Amersham
Place), and subsequently Keap1-DC (3mg) was allowed to form a complex with the
biotinylated compounds. Thereafter, 5 mg of 6His-GST-Neh2(1-56) or of BSA
(A-2135, Sigma-Aldrich) was added. The pull-down complexes were washed with
pull-down assay buffer. The bound proteins were analysed by NuPAGE system
followed by Coomassie brilliant blue staining.
Bioinformatics analysis. Genes in microarray analysis and metabolic
intermediates in metabolomics analysis were mapped to the identiﬁers deﬁned in
the KEGG database (downloaded on 21 May 2014). The number of genes and
metabolic intermediates in each category of KEGG with more than a cutoff
was counted. The reference sets in the enrichment analyses for microarray and
metabolomics analysis were the number of genes in mouse genome and the
number of whole metabolic intermediates estimated to be present from the
genome, respectively. If a gene is mapped to an enzyme reaction deﬁned in KEGG,
the substrate and product compounds were regarded as present in the species
and the number of whole metabolic intermediates to be present was estimated.
Subsequently, signiﬁcant enriched KEGG categories in both microarray and
metabolomics analyses were extracted based on FDR adjusted P valueso0.05
(ref. 66) from the ﬁsher’s exact test performed by using R (http://www.
r-project.org/).
Statistical analysis. Values, including those displayed in the graphs, represent
means±s.e.m. Statistical analyses were performed using the unpaired t-test (Welch
t-test). A P value less than 0.05 denoted statistical signiﬁcance.
Data availability. The structure data that support the ﬁndings of this study
have been deposited in the RCSB Protein Data Bank with PDB ID code ‘4ZY3
(http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZY3)’.
The microarray data relative to the genetic modiﬁed mice and to chemical
compound-treated cells that support the ﬁndings of this study have been deposited
in GEO respectively with the primary accession codes ‘GSE65174 (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65174)’ and ‘GSE68679
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68679)’.
The coordinates of the structure of K67 bound to Keap1-DC have been
deposited in the RCSB Protein Data Bank under PDB ID code 4ZY3.
References
1. Moscat, J. & Diaz-Meco, M. T. p62 at the crossroads of autophagy, apoptosis,
and cancer. Cell 137, 1001–1004 (2009).
2. Moscat, J. & Diaz-Meco, M. T. Feedback on fat: p62-mTORC1-autophagy
connections. Cell 147, 724–727 (2011).
3. Rogov, V., Dotsch, V., Johansen, T. & Kirkin, V. Interactions between
autophagy receptors and ubiquitin-like proteins form the molecular basis for
selective autophagy. Mol. Cell 53, 167–178 (2014).
4. Bjorkoy, G. et al. p62/SQSTM1 forms protein aggregates degraded by
autophagy and has a protective effect on huntingtin-induced cell death. J. Cell
Biol. 171, 603–614 (2005).
5. Geisler, S. et al. PINK1/Parkin-mediated mitophagy is dependent on VDAC1
and p62/SQSTM1. Nat. Cell Biol. 12, 119–131 (2010).
6. Dupont, N. et al. Shigella phagocytic vacuolar membrane remnants participate
in the cellular response to pathogen invasion and are regulated by autophagy.
Cell Host Microbe 6, 137–149 (2009).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12030
14 NATURE COMMUNICATIONS | 7:12030 | DOI: 10.1038/ncomms12030 |www.nature.com/naturecommunications
7. Komatsu, M. et al. Homeostatic levels of p62 control cytoplasmic inclusion
body formation in autophagy-deﬁcient mice. Cell 131, 1149–1163 (2007).
8. Bae, S. H. et al. Sestrins activate Nrf2 by promoting p62-dependent autophagic
degradation of Keap1 and prevent oxidative liver damage. Cell Metab. 17,
73–84 (2013).
9. Ichimura, Y. et al. Phosphorylation of p62 activates the Keap1-Nrf2 pathway
during selective autophagy. Mol. Cell 51, 618–631 (2013).
10. Jain, A. et al. p62/SQSTM1 is a target gene for transcription factor NRF2
and creates a positive feedback loop by inducing antioxidant response
element-driven gene transcription. J. Biol. Chem. 285, 22576–22591 (2010).
11. Komatsu, M. et al. The selective autophagy substrate p62 activates the stress
responsive transcription factor Nrf2 through inactivation of Keap1. Nat. Cell
Biol. 12, 213–223 (2010).
12. Lau, A. et al. A noncanonical mechanism of Nrf2 activation by autophagy
deﬁciency: direct interaction between Keap1 and p62. Mol. Cell Biol. 30,
3275–3285 (2010).
13. Taguchi, K. et al. Keap1 degradation by autophagy for the maintenance of
redox homeostasis. Proc. Natl. Acad. Sci. USA 109, 13561–13566 (2012).
14. Taguchi, K., Motohashi, H. & Yamamoto, M. Molecular mechanisms of the
Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 16,
123–140 (2011).
15. Jaramillo, M. C. & Zhang, D. D. The emerging role of the Nrf2-Keap1 signaling
pathway in cancer. Genes Dev. 27, 2179–2191 (2013).
16. Inami, Y. et al. Persistent activation of Nrf2 through p62 in hepatocellular
carcinoma cells. J. Cell Biol. 193, 275–284 (2011).
17. Takamura, A. et al. Autophagy-deﬁcient mice develop multiple liver tumors.
Genes Dev. 25, 795–800 (2011).
18. Ni, H. M. et al. Nrf2 promotes the development of ﬁbrosis and tumorigenesis in
mice with defective hepatic autophagy. J. Hepatol. 61, 617–625 (2014).
19. Zatloukal, K. et al. p62 Is a common component of cytoplasmic inclusions in
protein aggregation diseases. Am. J. Pathol. 160, 255–263 (2002).
20. Marcotte, D. et al. Small molecules inhibit the interaction of Nrf2 and the
Keap1 Kelch domain through a non-covalent mechanism. Bioorg. Med. Chem.
21, 4011–4019 (2013).
21. Duran, A. et al. The signaling adaptor p62 is an important NF-kappaB
mediator in tumorigenesis. Cancer Cell 13, 343–354 (2008).
22. Ling, J. et al. KrasG12D-induced IKK2/beta/NF-kappaB activation by IL-1alpha
and p62 feedforward loops is required for development of pancreatic ductal
adenocarcinoma. Cancer Cell 21, 105–120 (2012).
23. Mitsuishi, Y. et al. Nrf2 redirects glucose and glutamine into anabolic pathways
in metabolic reprogramming. Cancer Cell 22, 66–79 (2012).
24. Schulze, K. et al. Exome sequencing of hepatocellular carcinomas identiﬁes
new mutational signatures and potential therapeutic targets. Nat. Genet. 47,
505–511 (2015).
25. Soga, T. et al. Differential metabolomics reveals ophthalmic acid as an oxidative
stress biomarker indicating hepatic glutathione consumption. J. Biol. Chem.
281, 16768–16776 (2006).
26. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J.
Med. 359, 378–390 (2008).
27. Prestayko, A. W., D’Aoust, J. C., Issell, B. F. & Crooke, S. T. Cisplatin
(cis-diamminedichloroplatinum II). Cancer Treat. Rev. 6, 17–39 (1979).
28. Siddik, Z. H. Cisplatin: mode of cytotoxic action and molecular basis of
resistance. Oncogene 22, 7265–7279 (2003).
29. Reddy, N. M. et al. Genetic disruption of the Nrf2 compromises cell-cycle
progression by impairing GSH-induced redox signaling. Oncogene 27,
5821–5832 (2008).
30. Reddy, N. M. et al. Deﬁciency in Nrf2-GSH signaling impairs type II cell growth
and enhances sensitivity to oxidants. Am. J. Respir. Cell Mol. Biol. 37, 3–8 (2007).
31. Grifﬁth, O. W. & Meister, A. Potent and speciﬁc inhibition of glutathione
synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine).
J. Biol. Chem. 254, 7558–7560 (1979).
32. Xue, P. et al. Adipose deﬁciency of Nrf2 in ob/ob mice results in severe
metabolic syndrome. Diabetes 62, 845–854 (2013).
33. Komatsu, M. et al. Impairment of starvation-induced and constitutive
autophagy in Atg7-deﬁcient mice. J. Cell Biol. 169, 425–434 (2005).
34. Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes.
Nucleic Acids Res. 28, 27–30 (2000).
35. Harada, H. et al. Deﬁciency of p62/Sequestosome 1 causes hyperphagia due to
leptin resistance in the brain. J. Neurosci. 33, 14767–14777 (2013).
36. Padmanabhan, B. et al. Structural basis for defects of Keap1 activity provoked
by its point mutations in lung cancer. Mol. Cell 21, 689–700 (2006).
37. Fukutomi, T., Takagi, K., Mizushima, T., Ohuchi, N. & Yamamoto, M. Kinetic,
thermodynamic, and structural characterizations of the association between
Nrf2-DLGex degron and Keap1. Mol. Cell Biol. 34, 832–846 (2014).
38. Inoyama, D., Chen, Y., Huang, X., Beamer, L. J., Kong, A. N. & Hu, L.
Optimization of ﬂuorescently labeled Nrf2 peptide probes and the development
of a ﬂuorescence polarization assay for the discovery of inhibitors of
Keap1-Nrf2 interaction. J. Biomol. Screen. 17, 435–447 (2012).
39. Mizui, T. et al. Inhibition of hepatitis C virus replication by chloroquine
targeting virus-associated autophagy. J. Gastroenterol. 45, 195–203 (2010).
40. Sir, D., Chen, W. L., Choi, J., Wakita, T., Yen, T. S. & Ou, J. H. Induction of
incomplete autophagic response by hepatitis C virus via the unfolded protein
response. Hepatology 48, 1054–1061 (2008).
41. Sporn, M. B. & Liby, K. T. NRF2 and cancer: the good, the bad and the
importance of context. Nat. Rev. Cancer 12, 564–571 (2012).
42. Cancer Genome Atlas Research N. Comprehensive genomic characterization of
squamous cell lung cancers. Nature 489, 519–525 (2012).
43. Totoki, Y. et al. Trans-ancestry mutational landscape of hepatocellular
carcinoma genomes. Nature Genet. 46, 1267–1273 (2014).
44. Adam, J. et al. Renal cyst formation in Fh1-deﬁcient mice is independent of the
Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling.
Cancer Cell 20, 524–537 (2011).
45. Ooi, A. et al. An antioxidant response phenotype shared between hereditary
and sporadic type 2 papillary renal cell carcinoma. Cancer Cell 20, 511–523
(2011).
46. Singh, R. et al. Autophagy regulates lipid metabolism. Nature 458, 1131–1135
(2009).
47. Ezaki, J. et al. Liver autophagy contributes to the maintenance of blood glucose
and amino acid levels. Autophagy 7, 727–736 (2011).
48. White, E. The role for autophagy in cancer. J. Clin. Invest. 125, 42–46 (2015).
49. Guo, J. Y. et al. Autophagy suppresses progression of K-ras-induced lung
tumors to oncocytomas and maintains lipid homeostasis. Genes Dev. 27,
1447–1461 (2013).
50. Rao, S. et al. A dual role for autophagy in a murine model of lung cancer.
Nat. Commun. 5, 3056 (2014).
51. Jiang, P. & Mizushima, N. Autophagy and human diseases. Cell Res. 24, 69–79
(2014).
52. Zhi, X. & Zhong, Q. Autophagy in cancer. F1000Prime Rep. 7, 18 (2015).
53. Rosenfeldt, M. T. et al. p53 status determines the role of autophagy in
pancreatic tumour development. Nature 504, 296–300 (2013).
54. Berkers, C. R., Maddocks, O. D., Cheung, E. C., Mor, I. & Vousden, K. H.
Metabolic regulation by p53 family members. Cell Metab. 18, 617–633 (2013).
55. Kamei, D. et al. Microsomal prostaglandin E synthase-1 in both cancer cells
and hosts contributes to tumour growth, invasion and metastasis. Biochem. J.
425, 361–371 (2010).
56. Soga, T., Igarashi, K., Ito, C., Mizobuchi, K., Zimmermann, H. P. & Tomita, M.
Metabolomic proﬁling of anionic metabolites by capillary electrophoresis mass
spectrometry. Anal. Chem. 81, 6165–6174 (2009).
57. Soga, T. & Heiger, D. N. Amino acid analysis by capillary electrophoresis
electrospray ionization mass spectrometry. Anal. Chem. 72, 1236–1241 (2000).
58. Soga, T., Ohashi, Y., Ueno, Y., Naraoka, H., Tomita, M. & Nishioka, T.
Quantitative metabolome analysis using capillary electrophoresis mass
spectrometry. J. Proteome Res. 2, 488–494 (2003).
59. Soga, T., Ueno, Y., Naraoka, H., Ohashi, Y., Tomita, M. & Nishioka, T.
Simultaneous determination of anionic intermediates for Bacillus subtilis
metabolic pathways by capillary electrophoresis electrospray ionization mass
spectrometry. Anal. Chem. 74, 2233–2239 (2002).
60. Sugimoto, M., Wong, D. T., Hirayama, A., Soga, T. & Tomita, M. Capillary
electrophoresis mass spectrometry-based saliva metabolomics identiﬁed oral,
breast and pancreatic cancer-speciﬁc proﬁles. Metabolomics 6, 78–95 (2010).
61. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in
oscillation mode. Macromol. Crystallogr. A 276, 307–326 (1997).
62. Vagin, A. & Teplyakov, A. Molecular replacement with MOLREP. Acta
Crystallogr. D Biol. Crystallogr. 66, 22–25 (2010).
63. Emsley, P & Cowtan, K. Coot: model-building tools for molecular graphics.
Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132 (2004).
64. Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Reﬁnement of macromolecular
structures by the maximum-likelihood method. Acta Crystallogr. D Biol.
Crystallogr. 53, 240–255 (1997).
65. Wallace, A. C., Laskowski, R. A. & Thornton, J. M. LIGPLOT: a program to
generate schematic diagrams of protein-ligand interactions. Protein Eng. 8,
127–134 (1995).
66. Storey, J. D. & Tibshirani, R. Statistical signiﬁcance for genomewide studies.
Proc. Natl. Acad. Sci. USA 100, 9440–9445 (2003).
Acknowledgements
We thank Y. Matsuda (Niigata University) for his suggestions and advice on anti-tumour
drug studies, and K. Kanno and A. Yabashi (Fukushima Medical University School of
Medicine) for their help with histological studies. This work was supported by the
Platform for Drug Discovery, Informatics and Structural Life Science. The crystal-
lographic studies were performed at synchrotron beamline BL44XU at SPring-8 under
the Cooperative Research Program of the Institute for Protein Research, Osaka
University (Proposal Nos. 2014A6952 and 2014B6952). This work was supported by a
Grant-in-Aid for Scientiﬁc Research on Innovative Areas (25111006 to M.K. and S.W.),
a Grant-in-Aid for Scientiﬁc Research (A) (26253019 to M.K.), the Project for
Development of Innovative Research on Cancer Therapeutics (P-DIRECT) (15653010 to
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12030 ARTICLE
NATURE COMMUNICATIONS | 7:12030 | DOI: 10.1038/ncomms12030 |www.nature.com/naturecommunications 15
M.K., T. Mizushima and S.W.), the Takeda Science Foundation (to M.K.), the
A3 Foresight Program of the Japan Society of the Promotion of Science (JSPS)
(to M.-S.L. and M.K.) and the Global Research Laboratory Grant (to M.-S.L. and M.K.).
Author contributions
M.K., M.-S.L., H.M., K. Tanaka and M.Y. designed and directed the study. M.K. wrote
the manuscript. T. Saito, Y.I., K. Taguchi, T. Suzuki, T.I, T. Fukutomi, M. Obata,
T. Fujimura and T. Ueno carried out the biochemical and cell biological experiments.
T. Saito, K. Taguchi and T. Kouno performed most of the experiments that characterized
the knockout mice. Structural analyses were completed by T. Mizushima, and K. Takagi.
Y.H., M.N., T. Uemura and S.W. performed histological and microscopic analyses.
Metabolomic analyses were done by M. Ohishi, K.E. and T. Soga. Y.N. carried out
microarray analyses. S.O. performed bioinformatic analyses. H.K., T. Okabe and
T.N. provided diverse screening instrumentation, compound libraries and expertise, and
Y.I., R.I. and Y.T. conducted the high-throughput screening. R.O., D.Y., K. Takahashi,
T. Ohe and T. Mashino synthesized chemical compounds. J.P. provided Nrf2-conditional
knockout mice. All authors discussed the results and commented on the manuscript.
Additional information
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing ﬁnancial interests: The authors declare no competing ﬁnancial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Saito, T. et al. p62/Sqstm1 promotes malignancy of
HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic
reprogramming. Nat. Commun. 7:12030 doi: 10.1038/ncomms12030 (2016).
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise
in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material.
To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12030
16 NATURE COMMUNICATIONS | 7:12030 | DOI: 10.1038/ncomms12030 |www.nature.com/naturecommunications
